Content
In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio. Thermo Scientific products address a range of needs from sample, material characterization, and chemical analysis to clinical diagnoses and biological-based therapeutics manufacturing. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. Discover the resources that match your professional development interests, a culture that welcomes your ideas, and opportunities that only a global leader can provide. Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more. In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus.
This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition. Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems. In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing. In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.
In 1925, the company purchased Montreal-based Scientific Supplies, Ltd. Fisher became a supplier of lab equipment and reagents for the area's industrial research. Discover exclusive savings on ultra-low temperature freezers and laboratory equipment trusted by researchers worldwide. Save on equipment, consumables, and more all year long with Spotlight special offers.
Upgrade Your Lab with Thermo Scientific Equipment
In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. In October 2025, Thermo Fisher announced a deal to acquire Clario Holdings—an endpoint data management solutions provider—for $8.88 billion in cash from a shareholder group including Novo Holding. In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash). In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies. Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to support the development and production of new mRNA-based COVID-19 vaccines.
Grab Deals Before They're Gone
In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6 billion from Nordic Capital. In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement. In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash.
In February 2025, Thermo Fisher announced the acquisition of Solventum’s purification and filtration business for $4.1 billion. In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash. In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products. In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops adrian portelli casino app reagents for cell transfection, neurobiology and stem cell research.
About Thermo Scientific
In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients. The collaboration was designed to scale up the manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as President–Americas. After the merger creating Thermo Fisher Scientific in 2006, he was named Executive Vice President and President of its Analytical Technologies business, and in 2008 he became the company’s Chief Operating Officer. In July 2025, Thermo Fisher added drug manufacturing capabilities in the United States through its purchase of a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.